SGEN Stock Overview
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally.
No risks detected for SGEN from our risk checks.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$158.67|
|52 Week High||US$202.60|
|52 Week Low||US$133.20|
|1 Month Change||-12.09%|
|3 Month Change||4.24%|
|1 Year Change||-11.93%|
|3 Year Change||155.75%|
|5 Year Change||137.07%|
|Change since IPO||1,823.27%|
Recent News & Updates
|SGEN||US Biotechs||US Market|
Return vs Industry: SGEN underperformed the US Biotechs industry which returned 2% over the past year.
Return vs Market: SGEN underperformed the US Market which returned 17.8% over the past year.
|SGEN Average Weekly Movement||4.1%|
|Biotechs Industry Average Movement||8.8%|
|Market Average Movement||6.1%|
|10% most volatile stocks in US Market||14.9%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: SGEN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: SGEN's weekly volatility (4%) has been stable over the past year.
About the Company
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of metastatic urothelial cancers; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops Tisotumab Vedotin for metastatic cervical cancer and other solid tumors; ladiratuzumab vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases.
Seagen Fundamentals Summary
|SGEN fundamental statistics|
Is SGEN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SGEN income statement (TTM)|
|Cost of Revenue||US$1.43b|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-1.82|
|Net Profit Margin||-19.06%|
How did SGEN perform over the long term?See historical performance and comparison
Is Seagen undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: SGEN ($158.67) is trading below our estimate of fair value ($333.48)
Significantly Below Fair Value: SGEN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: SGEN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: SGEN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SGEN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SGEN is overvalued based on its PB Ratio (9.2x) compared to the US Biotechs industry average (2.7x).
How is Seagen forecast to perform in the next 1 to 3 years based on estimates from 20 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SGEN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: SGEN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: SGEN's is expected to become profitable in the next 3 years.
Revenue vs Market: SGEN's revenue (31.6% per year) is forecast to grow faster than the US market (10.1% per year).
High Growth Revenue: SGEN's revenue (31.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SGEN's Return on Equity is forecast to be high in 3 years time (23.5%)
How has Seagen performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SGEN is currently unprofitable.
Growing Profit Margin: SGEN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SGEN is unprofitable, but has reduced losses over the past 5 years at a rate of 36.1% per year.
Accelerating Growth: Unable to compare SGEN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SGEN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).
Return on Equity
High ROE: SGEN has a negative Return on Equity (-10.51%), as it is currently unprofitable.
How is Seagen's financial position?
Financial Position Analysis
Short Term Liabilities: SGEN's short term assets ($3.1B) exceed its short term liabilities ($698.4M).
Long Term Liabilities: SGEN's short term assets ($3.1B) exceed its long term liabilities ($114.5M).
Debt to Equity History and Analysis
Debt Level: SGEN is debt free.
Reducing Debt: SGEN has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SGEN has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if SGEN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Seagen current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SGEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SGEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SGEN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SGEN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SGEN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Clay Siegall (60 yo)
Dr. Clay B. Siegall, Ph D., co-founded Seagen Inc. (formerly known as Seattle Genetics, Inc.). in 1998 and has been its Chief Executive Officer since November 2002 and its President since June 2000. Dr. Si...
CEO Compensation Analysis
Compensation vs Market: Clay's total compensation ($USD16.49M) is above average for companies of similar size in the US market ($USD11.11M).
Compensation vs Earnings: Clay's compensation has increased whilst the company is unprofitable.
Experienced Management: SGEN's management team is seasoned and experienced (6.1 years average tenure).
Experienced Board: SGEN's board of directors are seasoned and experienced ( 14.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Seagen Inc.'s employee growth, exchange listings and data sources
- Name: Seagen Inc.
- Ticker: SGEN
- Exchange: NasdaqGS
- Founded: 1997
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$28.937b
- Shares outstanding: 182.86m
- Website: https://www.seagen.com
Number of Employees
- Seagen Inc.
- 21823 30th Drive SE
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/12/02 23:30|
|End of Day Share Price||2021/12/02 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.